IP Library › Granted Patent US 12,577,310
Granted Patent B2
US 12,577,310 · App. 18/247,653 · Granted Mar 17, 2026

Caninized antibodies to canine interleukin-31 receptor

Inventors: Mohamad Morsey (Omaha, NE); Yuanzheng Zhang (Somerset, NJ); Anasuya Saha (Fremont, CA)
Assignee: INTERVET INC.
C07K16/2866A61P17/04C12N15/63C07K2317/20C07K2317/24C07K2317/53C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,577,310
App. No.
18/247,653
Granted
Mar 17, 2026
Kind
B2
Abstract

The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine IL-31 receptor alpha, and that can block the binding of canine IL-31 to canine IL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.

Claims (71)

1 . An isolated mammalian antibody or antigen binding fragment thereof that binds canine interleukin-31 receptor alpha (canine IL-31RA), wherein said antibody comprises a set of six complementary determining regions (CDRs), three of which are heavy chain CDRs: CDR heavy 1 (HCDR1), CDR heavy 2 (HCDR2) and CDR heavy 3 (HCDR3) and three of which are light chain CDRs: CDR light 1 (LCDR1), CDR light 2 (LCDR2), and CDR light 3 (LCDR3); and

wherein the set of six CDRs are selected from the group of sets consisting of (i), (ii), and (iii); wherein for set (i):

HCDR1 comprises the amino acid sequence of SEQ ID NO: 13;

HCDR2 comprises the amino acid sequence of SEQ ID NO: 14;

HCDR3 comprises the amino acid sequence of SEQ ID NO: 15;

LCDR1 comprises the amino acid sequence of SEQ ID NO: 16;

LDR2 comprises the amino acid sequence of SEQ ID NO: 17; and

LCDR3 comprises the amino acid sequence of SEQ ID NO: 18;

wherein for set (ii):

HCDR1 comprises the amino acid sequence of SEQ ID NO: 19;

HCDR2 comprises the amino acid sequence of SEQ ID NO: 20;

HCDR3 comprises the amino acid sequence of SEQ ID NO: 21;

LCDR1 comprises the amino acid sequence of SEQ ID NO: 22;

LDR2 comprises the amino acid sequence of SEQ ID NO: 23; and

LCDR3 comprises the amino acid sequence of SEQ ID NO: 24; and

wherein for set (iii)

HCDR1 comprises the amino acid sequence of SEQ ID NO: 25;

HCDR2 comprises the amino acid sequence of SEQ ID NO: 26;

HCDR3 comprises the amino acid sequence of SEQ ID NO: 27;

LCDR1 comprises the amino acid sequence of SEQ ID NO: 28;

LDR2 comprises the amino acid sequence of SEQ ID NO: 29; and

LCDR3 comprises the amino acid sequence of SEQ ID NO: 30.

2 . The isolated mammalian antibody or antigen binding fragment thereof of claim 1 ,

wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 13;

wherein HCDR2 comprises the amino acid sequence of SEQ ID NO: 14;

wherein HCDR3 comprises the amino acid sequence of SEQ ID NO: 15;

wherein LCDR1 comprises the amino acid sequence of SEQ ID NO: 16;

wherein LDR2 comprises the amino acid sequence of SEQ ID NO: 17; and

wherein LCDR3 comprises the amino acid sequence of SEQ ID NO: 18.

3 . The isolated mammalian antibody or antigen binding fragment thereof of claim 2 , that when bound to canine IL-31RA the antibody binds to an epitope comprised by the amino acid sequence selected from the group consisting of SEQ ID NO: 102, SEQID NO: 103, and both SEQ ID NO: 102 and SEQID NO: 103.

4 . The isolated mammalian antibody or antigen binding fragment thereof of claim 1 ,

wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 19;

wherein HCDR2 comprises the amino acid sequence of SEQ ID NO: 20;

wherein HCDR3 comprises the amino acid sequence of SEQ ID NO: 21;

wherein LCDR1 comprises the amino acid sequence of SEQ ID NO: 22;

wherein LDR2 comprises the amino acid sequence of SEQ ID NO: 23; and

wherein LCDR3 comprises the amino acid sequence of SEQ ID NO: 24.

5 . The isolated mammalian antibody or antigen binding fragment thereof of claim 1 ,

wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 25;

wherein HCDR2 comprises the amino acid sequence of SEQ ID NO: 26;

wherein HCDR3 comprises the amino acid sequence of SEQ ID NO: 27;

wherein LCDR1 comprises the amino acid sequence of SEQ ID NO: 28;

wherein LDR2 comprises the amino acid sequence of SEQ ID NO: 29; and

wherein LCDR3 comprises the amino acid sequence of SEQ ID NO: 30.

6 . The isolated mammalian antibody or antigen binding fragment thereof of claim 5 , that when bound to canine IL-31RA the antibody binds to an epitope comprised by the amino acid sequence of SEQ ID NO: 101.

7 . The isolated mammalian antibody or antigen binding fragment thereof of claim 1 , wherein the antibody and antigen binding fragment thereof bind canine IL-31RA and block the binding of canine IL-31RA to canine interleukin-31.

8 . The isolated mammalian antibody or antigen binding fragment thereof of claim 7 , that is a caninized antibody or a caninized antigen binding fragment thereof.

9 . The caninized antibody or antigen binding fragment thereof of claim 8 , that comprises a hinge region that comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, and SEQ ID NO: 82.

10 . The caninized antibody or antigen binding fragment thereof of claim 8 , that comprises a heavy chain comprising a modified canine IgG-B (IgG-Bm) comprising the amino acid sequence of SEQ ID NO: 78.

11 . The caninized antibody or antigen binding fragment thereof of claim 8 , wherein the caninized IL-31RA antibody comprises a light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, and SEQ ID NO: 93; and a heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 88 and SEQ ID NO: 89.

12 . The caninized antibody or antigen binding fragment thereof of claim 11 , wherein the caninized IL-31RA antibody comprises:

a light chain comprising the amino acid sequence of SEQ ID NO: 92 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 88; or

a light chain comprising the amino acid sequence of SEQ ID NO: 93 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 88; or

a light chain comprising the amino acid sequence of SEQ ID NO: 92 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 89; or

a light chain comprising the amino acid sequence of SEQ ID NO: 93 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 89.

13 . The caninized antibody or antigen binding fragment thereof of claim 8 , wherein the caninized IL-31RA antibody comprises a light chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99; and SEQ ID NO: 100; and a heavy chain comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 95 and SEQ ID NO: 96.

14 . The caninized antibody or antigen binding fragment thereof of claim 13 , wherein the caninized IL-31RA antibody comprises:

a light chain comprising the amino acid sequence of SEQ ID NO: 97 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 95; or

a light chain comprising the amino acid sequence of SEQ ID NO: 98 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 95; or

a light chain comprising the amino acid sequence of SEQ ID NO: 99 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 95; or

a light chain comprising the amino acid sequence of SEQ ID NO: 97 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 96; or

a light chain comprising the amino acid sequence of SEQ ID NO: 98 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 96; or

a light chain comprising the amino acid sequence of SEQ ID NO: 99 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 96 or

a light chain comprising the amino acid sequence of SEQ ID NO: 97 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; or

a light chain comprising the amino acid sequence of SEQ ID NO: 98 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; or

a light chain comprising the amino acid sequence of SEQ ID NO: 99 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 100.

15 . An isolated nucleic acid that encodes a chain of the caninized antibody of claim 8 , selected from the group consisting of a heavy chain of the caninized antibody or antigen binding fragment thereof, a light chain of the caninized antibody or antigen binding fragment thereof, or both the heavy chain of the caninized antibody or antigen binding fragment thereof and the light chain of the caninized antibody or antigen binding fragment thereof.

16 . An expression vector comprising the isolated nucleic acid of claim 15 .

17 . A host cell comprising the expression vector of Claim 16 .

18 . A pharmaceutical composition comprising the caninized antibody or antigen binding fragment thereof of claim 8 , and a pharmaceutically acceptable carrier or diluent.

19 . A method of aiding in the blocking the pruritus associated with atopic dermatitis, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 18 .

Assignments (4)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2023
From: SAHA, ANASUYA
To: MERCK SHARP & DOHME CORP.
Reel/Frame 063202/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2023
From: MERCK SHARP & DOHME CORP.
To: INTERVET INC.
Reel/Frame 063203/0060 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2023
From: MORSEY, MOHAMAD; ZHANG, YUANZHENG
To: INTERVET INC.
Reel/Frame 063203/0116 →
Continuity (6)
Provisional Application 63235258 · Aug 20, 2021
Provisional Application 63235257 · Aug 20, 2021
Provisional Application 63127184 · Dec 18, 2020
Provisional Application 63092296 · Oct 15, 2020
Provisional Application 63092294 · Oct 15, 2020
Related Publication 20230391879A1 · Dec 7, 2023
References Cited (22)
US 20130022616A1 · Bammert et al. · 2013 [cited by applicant]
US 20200239563A1 · Piketty · 2020 [cited by applicant]
CN 110563844A · 2019 [cited by third party]
JP 2014529295A · 2014 [cited by applicant]
JP 2021509103A · 2021 [cited by applicant]
JP 2023545182A · 2023 [cited by applicant]
RU 2016129113A · 2018 [cited by applicant]
WO WO2020157636A1 · 2020 [cited by applicant]
Grimstad et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Experimental Dermatology, 18, 35-43, 2008. (Year: 2008). [cited by examiner]
Li et al. Preparation of anti canine interleukin 31 receptor alpha polyclonal antibody and evaluation of its therapeutic effect in canine atopic dermatitis. Animal Diseases (2023) 3:26. (Year: 2023). [cited by examiner]
Siniewicz-Luzenczyk et al. Correlation between serum interleukin-31 level and the severity of disease in children with atopic dermatitis. Postepy Dermatol Alergol . Oct. 2013;30(5):282-5. (Year: 2013). [cited by examiner]
Badri et al., 2016, “Optimization of radiation dosing schedules for proneural glioblastoma,” J. Math. Biol., 72(5):1301-1336 (Epub 2015). [cited by applicant]
Baylot et al., 2017, “Chapter 13—TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression,” Results Probl. Cell Differ., 64:255-261. [cited by applicant]
Mariuzza et al., 1987, “The structural basis of antigen-antibody recognition,” Annu. Rev. Biophys. Biophys. Chem., 16:139-159. [cited by applicant]
Roitt et al., 2000, “Humanized antibodies to amyloid beta”, in Immunology, Moscow, Mir, pp. 110-111, in Russian with English translation (9 pages). [cited by applicant]
Singer et al., 1998, “Genes and Genomes,” Moscow, Mir, translation from English, 1:63-64, in Russian with machine English translation (8 pages). [cited by applicant]
Venereau et al., 2010, “Definition and characterization of an inhibitor for interleukin-31,” J. Biol. Chem., 285(20):14955-14963. [cited by applicant]
Zhang et al., 2008, “Structures and biological functions of IL-31 and IL-31 receptors,” Cytokine Growth Factor Rev., 19(5-6):347-356. [cited by applicant]
Kabashima et al., 2020, “Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus,” N. Engl. J. Med., 383(2):141-150 and Supplementary Appendix (37 pages). [cited by applicant]
Ruzicka et al., 2017, “Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis,” N. Engl. J. Med., 376(9):826-835 and Supplementary Appendix (32 pages). [cited by applicant]
Venereau et al., “Definition and Characterization of an Inhibitor for Interleukin-31,” Journal of Biological Chemistry, vol. 285, No. 20, May 14, 2010, pp. 14955-14963. [cited by third party]
Zhang et al., “Structures and biological functions of IL-31 and IL-31 receptors,” Cytokine Growth Factor Rev., vol. 19, Issue 5-6, 2008, pp. 347-356. [cited by third party]